Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
| Fund | ||||||||
|---|---|---|---|---|---|---|---|---|
| AZN.L | +2.98% | +8.86% | +12.16% | +13.68% | +10.48% | +0.76% | +13.19% | +46.68% |
| SCBIHEALT(SSFE) | +12.60% | +3.34% | +6.78% | +8.27% | +11.10% | +23.33% | +17.20% | +20.95% |
| SCBGHCA | +10.67% | +2.27% | +5.01% | +6.41% | +3.72% | +14.55% | +19.95% | +40.28% |
| BCARERMF | +15.33% | +1.81% | +5.38% | +6.86% | +7.46% | +18.07% | +23.62% | +30.94% |
| LHHEALTH-DSSF | +13.20% | +2.48% | +5.69% | +9.34% | +9.72% | +19.03% | +19.06% | +16.85% |
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
Excludes AZN.L: money market or bond funds, or no holdings data yet
| SCBGHCA | LHHEALTH-DSSF | |
|---|---|---|
| Held by both | ||
 Eli Lilly and Co | 9.72% | 9.14% |
 Johnson & Johnson | 7.87% | 9.43% |
 Unitedhealth Group | 4.32% | 6.16% |
 AstraZeneca | 3.75% | 3.72% |
 Novartis | 2.76% | 4.20% |
 Roche | 2.71% | 5.15% |
 Merck & | 2.38% | 6.22% |
| Only in SCBGHCA | ||
 ABBVIE | 4.99% | N/A |
 Thermo Fisher | 3.39% | N/A |
 argenx | 2.48% | N/A |
| Only in LHHEALTH-DSSF | ||
 Vertex Pharmaceuticals | N/A | 3.66% |
 Gilead Sciences | N/A | 3.61% |
 Bristol-Myers Squibb Co | N/A | 2.80% |
30 Dec 2025 → 30 Oct 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| BCARERMF | +15.33% | 16.01% | 0.96 |
| LHHEALTH-DSSF | +13.20% | 16.10% | 0.82 |
| SCBIHEALT(SSFE) | +12.60% | 17.46% | 0.72 |
| SCBGHCA | +10.67% | 16.91% | 0.63 |
| AZN.L | +2.98% | 29.51% | 0.10 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | AZN.L | SCBIHEALT(SSFE) | SCBGHCA | BCARERMF | LHHEALTH-DSSF |
|---|---|---|---|---|---|
Fund details | |||||
| Fund size | N/A | 10.22 million | 958 million | 8,627 million | 0.49 million |
| Inception date | N/A | 29 Jun 2021 | 2 Sep 2015 | 19 May 2015 | 29 Sep 2021 |
| Master fund | N/A | BNP Paribas Funds Health Care Innovators | Janus Henderson Global Life Sciences Fund | Wellington Global Health Care Equity Fund | AB International Health Care Portfolio |
| Dividend policy | N/A | Pays | Does not pay | Does not pay | Pays |
Risk and currency hedging | |||||
| Risk level | N/A | 7 | 7 | 7 | 7 |
| Hedging policy | N/A | Hedged at the manager's discretion | Almost fully hedged | Hedged at the manager's discretion | Hedged at the manager's discretion |
| Share hedged | N/A | 82.39% | 100.09% | 45.53% | 80.26% |
Minimum purchase and redemption | |||||
| First purchase | N/A | 1 THB | 1 THB | 500 THB | No minimum |
| Subsequent purchase | N/A | 1 THB | 1 THB | 500 THB | No minimum |
| Redemption (amount) | N/A | No minimum | 1 THB | No minimum | No minimum |
| Redemption (units) | N/A | No minimum | No minimum | No minimum | No minimum |
| Balance (amount) | N/A | No minimum | 1 THB | No minimum | No minimum |
| Balance (units) | N/A | No minimum | No minimum | No minimum | No minimum |
Order cut-off and redemption payment | |||||
| Buy before | N/A | 15:30 | 15:30 | 15:30 | 14:00 |
| Redeem before | N/A | 15:30 | 15:30 | 15:30 | 14:00 |
| Redemption paid | N/A | T+4 | T+5 | T+4 | T+4 |
